Jean Yves Pierga

Summary

Affiliation: Institut Curie
Country: France

Publications

  1. ncbi request reprint Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response
    J Y Pierga
    Medical Oncology Department, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex 05, France
    Eur J Cancer 39:1089-96. 2003
  2. doi request reprint High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
    J Y Pierga
    Department of Medical Oncology, Institut Curie, Paris, France
    Ann Oncol 23:618-24. 2012
  3. ncbi request reprint Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients
    Jean Yves Pierga
    Medical Oncology Department, Unité Mixte de Recherche 144 Centre National de la Recherche Scientifique, Paris, France
    Clin Cancer Res 10:1392-400. 2004
  4. ncbi request reprint Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age
    J Y Pierga
    Departement d Oncologie Medicale, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex 05, France
    Breast 13:369-75. 2004
  5. ncbi request reprint Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients
    Jean Yves Pierga
    Medical Oncology Department, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex 05, France
    Int J Cancer 114:291-8. 2005
  6. pmc Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer
    J Y Pierga
    Medical Oncology Department, Institut Curie, 75248 Paris Cedex 05, France
    Br J Cancer 89:539-45. 2003
  7. ncbi request reprint Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
    J Y Pierga
    Medical Oncology Department, Institut Curie, Paris, France
    Ann Oncol 12:231-7. 2001
  8. ncbi request reprint Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy
    J Y Pierga
    Medical Oncology Department, Institut Curie, Paris Cedex 05, France
    Cancer 91:1079-89. 2001
  9. doi request reprint Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial
    Jean Yves Pierga
    Institut Curie, Paris, France
    Clin Cancer Res 14:7004-10. 2008
  10. doi request reprint A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
    Jean Yves Pierga
    Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    Breast Cancer Res Treat 122:429-37. 2010

Detail Information

Publications98

  1. ncbi request reprint Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response
    J Y Pierga
    Medical Oncology Department, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex 05, France
    Eur J Cancer 39:1089-96. 2003
    ..Clinical response could be used as a surrogate marker for evaluation of the efficacy of neoadjuvant chemotherapy before assessment of the pathological response...
  2. doi request reprint High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
    J Y Pierga
    Department of Medical Oncology, Institut Curie, Paris, France
    Ann Oncol 23:618-24. 2012
    ..Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but comparisons with serum tumor markers (CA 15-3, carcinoembryonic antigen and lactate dehydrogenase) variations are needed...
  3. ncbi request reprint Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients
    Jean Yves Pierga
    Medical Oncology Department, Unité Mixte de Recherche 144 Centre National de la Recherche Scientifique, Paris, France
    Clin Cancer Res 10:1392-400. 2004
    ....
  4. ncbi request reprint Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age
    J Y Pierga
    Departement d Oncologie Medicale, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex 05, France
    Breast 13:369-75. 2004
    ..Prognostic factors are the same as in younger postmenopausal patients. More than 50% of these patients died from a cause other than their breast cancer...
  5. ncbi request reprint Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients
    Jean Yves Pierga
    Medical Oncology Department, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex 05, France
    Int J Cancer 114:291-8. 2005
    ..A larger study would be useful to confirm the importance of uPAR to define higher risk subgroups of breast cancer patients with micrometastatic disease...
  6. pmc Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer
    J Y Pierga
    Medical Oncology Department, Institut Curie, 75248 Paris Cedex 05, France
    Br J Cancer 89:539-45. 2003
    ..In conclusion, viable tumour cells can be detected in the bone marrow of breast cancer patients. Their proliferative potential could be predictive of outcome and deserves further investigation...
  7. ncbi request reprint Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
    J Y Pierga
    Medical Oncology Department, Institut Curie, Paris, France
    Ann Oncol 12:231-7. 2001
    ..We addressed this question in a multivariate analysis evaluating response to chemotherapy as a factor influencing survival of patients with metastatic breast cancer...
  8. ncbi request reprint Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy
    J Y Pierga
    Medical Oncology Department, Institut Curie, Paris Cedex 05, France
    Cancer 91:1079-89. 2001
    ..The objective of the current study was to analyze the impact of adjuvant chemotherapy in comparison with other prognostic parameters on the outcome of a series of patients with breast carcinoma at time of metastatic recurrence...
  9. doi request reprint Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial
    Jean Yves Pierga
    Institut Curie, Paris, France
    Clin Cancer Res 14:7004-10. 2008
    ....
  10. doi request reprint A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
    Jean Yves Pierga
    Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    Breast Cancer Res Treat 122:429-37. 2010
    ..In HER2-positive tumor patients, trastuzumab added to ECD leads to increased pCR rates. It was the only combination to deserve further study according to the two-stage Fleming's design used in this trial...
  11. ncbi request reprint Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients
    J Y Pierga
    Department of Medical Oncology, Institut Curie, Paris, France
    Int J Biol Markers 19:23-31. 2004
    ..The presence of CK+ cells in bone marrow remains a strong independent prognostic factor in primary breast cancer...
  12. doi request reprint Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy?
    Caroline Daveau
    Department of Radiation Oncology, Institut Curie, Paris, France
    Int J Radiat Oncol Biol Phys 79:1452-9. 2011
    ..To determine whether the exclusive use of radiotherapy (ERT) could be a treatment option after complete clinical response (cCR) to neoadjuvant chemotherapy (NCT) for early breast cancer (EBC)...
  13. doi request reprint Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer
    Virginie Marchand
    Departments of Radiation Oncology Medical Oncology Biostatistics Surgery, Institut Curie, Paris, France
    Am J Clin Oncol 36:425-9. 2013
    ..This study aims to investigate prospectively the toxicities of adjuvant concurrent chemoradiotherapy versus radiotherapy alone...
  14. doi request reprint Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer
    Christophe Le Tourneau
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Clin Oncol 35:242-6. 2012
    ....
  15. doi request reprint Management of inflammatory breast cancer after neoadjuvant chemotherapy
    Soumya Abrous-Anane
    Department of Radiation Oncology, Institut Curie, Paris, France
    Int J Radiat Oncol Biol Phys 79:1055-63. 2011
    ..To assess the benefit of breast surgery for inflammatory breast cancer (IBC)...
  16. doi request reprint Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, Paris, France
    Clin Cancer Res 14:3306-11. 2008
    ..Clinical significance of disseminated tumor cells (DTC) in bone marrow of early breast cancer patients has been reported, but improvements in detection methods are needed...
  17. doi request reprint A prognostic DNA signature for T1T2 node-negative breast cancer patients
    Eleonore Gravier
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, Paris, France
    Genes Chromosomes Cancer 49:1125-34. 2010
    ..34; 95% confidence interval 1.01-11.02; P = 4.78 × 10(-2), Wald test). This study shows that tumor DNA contains important prognostic information that may help to predict metastasis in T1T2N0 tumors of the breast...
  18. pmc Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 8:e55901. 2013
    ..The present study aims to validate Ki67 as prognostic factor in a large cohort of early-stage (pT1-pT2, pN0) breast cancer patients...
  19. ncbi request reprint Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor
    Valerie Laurence
    Department of Medical Oncology, Institut Curie, Paris, France
    Am J Clin Oncol 28:301-9. 2005
    ..71%, P = 0.017) and poor pathologic response (5-year overall survival 44% vs.77%, P = 0.03). This retrospective study shows a high long-term survival rate with high-dose chemotherapy in adults...
  20. pmc Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma
    Fabien Reyal
    Departement de Chirurgie, Institut Curie, Paris, France
    PLoS ONE 7:e35184. 2012
    ..Since most of the genes included in the GG are involved in cell proliferation, we performed a retrospective study to compare the prognostic value of GG, Mitotic Index and Ki67 score...
  21. doi request reprint Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option
    Sophie Haberer
    Department of Radiation Oncology, Institut Curie, Paris, France
    Int J Radiat Oncol Biol Phys 82:e145-52. 2012
    ..To report clinical and pathologic characteristics and outcome of breast cancer (BC) after irradiation for Hodgkin's lymphoma (HL) in women treated at the Institut Curie, with a special focus on the breast-conserving option...
  22. pmc Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance
    Valerie Choesmel
    UMR144 CNRS, Research Division, Institut Curie, Paris, France
    Breast Cancer Res 6:R556-70. 2004
    ..In the present study, we have assessed the clinical relevance of current methods aimed at detecting rare disseminated carcinoma cells...
  23. pmc Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Breast Cancer Res 14:R29. 2012
    ..However, serum marker levels are also used for the same purpose, and no clear comparison has been reported to date...
  24. pmc The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 6:e20297. 2011
    ..The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy...
  25. ncbi request reprint [Targeting epidermal growth factor receptor in cancer of the breast]
    Veronique Dieras
    Departement d Oncologie Medicale, Institut Curie, 26, rue d Ulm, 75005 Paris
    Bull Cancer 90:S257-62. 2003
    ..However the complexity of erbB network requires the targeting of multiple molecular sites within the network and the characterization of tumor profiles in order to optimally select patients for these therapies...
  26. doi request reprint Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients
    Cyrus Chargari
    Department of Radiation Oncology, Institut Curie, Paris, France
    Int J Radiat Oncol Biol Phys 81:631-6. 2011
    ..To assess the use of trastuzumab concurrently with whole brain radiotherapy (WBRT) for patients with brain metastases from human epidermal growth factor receptor-2-positive breast cancer...
  27. pmc External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement
    David Hajage
    Department of Biostatistics, Institut Curie, Paris, France
    PLoS ONE 6:e27446. 2011
    ..We provide the validation of Adjuvant! Online algorithm on two breast cancer datasets, and we determined whether the accuracy of Adjuvant! Online is improved with other well-known prognostic factors...
  28. doi request reprint FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells
    Karla Perez-Toralla
    Macromolecules and Microsystems in Biology and Medicine, Institut Curie, Centre National de la Recherche Scientifique, Universite Pierre et Marie Curie, PSL Research University, UMR 168, 75005, Paris, France
    Methods Mol Biol 1547:211-220. 2017
    ..The FISH protocol can be fully automated, thus enabling its use in routine clinical practice...
  29. doi request reprint High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection
    Julien Autebert
    Institut Curie, Centre National de la Recherche Scientifique, Universite Pierre et Marie Curie, PSL Research University, Unité Mixte de Recherche 168, 75005 Paris, France
    Lab Chip 15:2090-101. 2015
    ..Finally, we demonstrated the possibility of detecting cancer-related PIK3CA gene mutation in 20 cells captured in the chip with a good correlation between the cell count and the quantitation value Cq of the post-capture qPCR...
  30. doi request reprint Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data
    Jean Yves Pierga
    Institut Curie, Paris, France Université Paris Descartes, Paris, France
    Clin Cancer Res 21:1298-304. 2015
    ..Here, we report the results of a preplanned survival analysis at 3 years of follow-up, along with the association between outcome and circulating biomarkers and pathologic complete response (pCR)...
  31. ncbi request reprint [Update on docetaxel and breast cancer]
    Veronique Dieras
    Departement d Oncologie Medicale, Institut Curie, 26, rue d Ulm, 75005 Paris
    Bull Cancer 91:409-17. 2004
    ..The integration of trastuzumab with taxane-based chemotherapy has already demonstrated high activity in metastatic breast cancer with overexpression of HER2 and adjuvant trials are ongoing...
  32. pmc Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 7:e47390. 2012
    ....
  33. doi request reprint Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy
    Ciprian Chira
    Department of Radiation Oncology, Breast Cancer Study Group, Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    J Neurooncol 105:401-8. 2011
    ..BBCT before WBRT was not associated with severe brain toxicity. Because of the limited number of pts, the different BBCT regimens, and important delays between treatments, these results must be confirmed prospectively...
  34. doi request reprint Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    Clin Exp Metastasis 25:871-5. 2008
    ..Dissemination of DTC in other host organ and/or epithelial-mesenchymal transition from cytokeratin-positive to cytokeratin-negative DTC may explain this observation...
  35. pmc Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
    J Y Pierga
    Medical Oncology Department, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, 75248, France
    Br J Cancer 83:1480-7. 2000
    ..In conclusion, patients with extensive nodal involvement after neoadjuvant chemotherapy have a very poor outcome. Second-line treatment should be considered in this population...
  36. doi request reprint Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells
    F C Bidard
    Department of Medical Oncology, Institut Curie, Paris, France
    Ann Oncol 19:496-500. 2008
    ..Detection of disseminated tumor cells (DTC) in bone marrow (BM) is an independent prognostic factor in early breast cancer. We evaluated the prognostic value of DTC detection in the BM of metastatic breast cancer patients...
  37. pmc MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
    Emeline Tabouret
    Institut Paoli Calmettes, Medical Oncology Department, Marseille, France
    Oncotarget 7:18531-40. 2016
    ..We examined the prognostic impact of MMP2 and MMP9 serum levels in BEVERLY-2 patients...
  38. doi request reprint Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Francesca Riva
    Laboratory of Circulating Tumor Biomarkers, Institut Curie, PSL Research University, SIRIC, Paris, France
    Clin Chem . 2017
    ....
  39. pmc Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
    Anne Sophie Hamy-Petit
    Institut Curie, PSL Research University, Translational Research Department, INSERM, U932 Immunity and Cancer, Residual Tumor and Response to Treatment Laboratory RT2Lab, F 75248, Paris, France
    Br J Cancer 114:44-52. 2016
    ..We investigated the factors predictive of pathological complete response (pCR), prognostic factors for disease-free survival (DFS), and interactions between pCR and DFS after neoadjuvant treatment...
  40. pmc Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris Cedex 05, France
    Breast Cancer Res 9:R24. 2007
    ..The present study was therefore designed to identify phenotypic and genetic alterations that distinguish MBCs from basal-like carcinomas (BLC)...
  41. ncbi request reprint [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]
    Patricia De Cremoux
    Unité de Pharmacologie, Institut Curie, 26, rue d Ulm, 75005 Paris, France
    Bull Cancer 91:917-27. 2004
    ..These trials were either comparative (for anastrozole) or sequential (for anastrozole, letrozole and exemestane). The issues of long term adverse effects (bone) and hormone treatment sequence remain to be addressed...
  42. doi request reprint Translating metastasis-related biomarkers to the clinic--progress and pitfalls
    François Clément Bidard
    Department of Medical Oncology, Institut Curie and Université Paris Descartes, 26 Rue d Ulm, 75005 Paris, France
    Nat Rev Clin Oncol 10:169-79. 2013
    ....
  43. doi request reprint Gastric metastasis of breast cancer: a single centre retrospective study
    Maher M Almubarak
    Department of Surgery, Curie Institute, Paris, France
    Dig Liver Dis 43:823-7. 2011
    ..Digestive metastasis of breast cancer are rare but when they do occur the stomach is one of the commoner sites...
  44. ncbi request reprint Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis
    Pascale Mariani
    Department of Surgical Oncology, Institut Curie, Paris, France
    Anticancer Res 30:4229-35. 2010
    ..We concluded there was a high concordance in the KRAS status between the primary tumour and metastases. More than one informative block and more sensitive assay may increase the accuracy of KRAS status determination...
  45. ncbi request reprint Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients
    Patricia De Cremoux
    Departement de Biologie des Tumeurs, Institut Curie, 26 Rue d Ulm, 75231 Paris Cedex, France
    Anticancer Res 29:1475-82. 2009
    ..This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients...
  46. doi request reprint Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer
    F C Bidard
    CirCe laboratory, Institut Curie, 26 Rue d Ulm, Paris, France
    Ann Oncol 21:729-33. 2010
    ..In this prospective study, we reported the clinical outcome of nonmetastatic breast cancer patients according to CTC detection...
  47. pmc Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
    Hélène Bonsang-Kitzis
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 10:e0144359. 2015
    ..Only a subset of patients achieves a pathologic complete response (pCR) after NAC and have a better outcome than patients with residual disease...
  48. pmc Helical tomotherapy for inoperable breast cancer: a new promising tool
    Ciprian Chira
    Department of Radiation Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Biomed Res Int 2013:264306. 2013
    ..We investigated the feasibility of helical tomotherapy (HT) for inoperable large breast tumors, after failing to achieve adequate treatment planning with conformal radiation techniques...
  49. doi request reprint Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast
    Anne Vincent-Salomon
    Institut Curie, Department of Tumor Biology, Paris, France
    Clin Cancer Res 14:1956-65. 2008
    ..To gain insight into genomic and transcriptomic subtypes of ductal carcinomas in situ of the breast (DCIS)...
  50. pmc Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France Laboratory of Circulating Cancer Biomarker, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Int J Breast Cancer 2013:130470. 2013
    ..We confirm that the detection of CTC is independently associated with a significantly worse outcome, but mainly during the first 3-4 years of follow-up. No prognostic impact is seen in patients who are still relapse-free at this moment...
  51. doi request reprint [Survival of breast cancers patients with meningeal carcinoma]
    Hélène Petithuguenin Gauthier
    Institut Curie, Departement d Oncologie Medicale, 26, rue d Ulm, 75005 Paris, France
    Bull Cancer 98:391-8. 2011
    ..The purpose of this study was to analyze clinical and biological responses as well as overall survival in MC patients (pts) of breast primary treated with intrathecal methotrexate (MTX)...
  52. doi request reprint The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study
    Lucas Caussa
    Department of Radiation Oncology, Institut Curie, 26, rue d Ulm, 75248 Paris Cedex 05, France
    Eur J Cancer 47:65-73. 2011
    ..To evaluate the skin and heart toxicity of a concurrent adjuvant trastuzumab-radiotherapy for breast cancer (BC), especially in the case of internal mammary chain (IMC) irradiation...
  53. doi request reprint Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
    Francesca Riva
    Institut Curie, PSL Research University, SIRIC, Laboratory of Circulating Tumor Biomarkers, Paris, France San Gerardo Hospital, Department of Medical Oncology, Monza, Italy
    Mol Oncol 10:481-93. 2016
    ..In this review, together with key biological findings, we summarize the clinical results obtained using "liquid biopsies" at the different stages of the disease, for early and metastatic diagnosis as well as monitoring during therapy. ..
  54. doi request reprint Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study
    Jean Yves Pierga
    Institut Curie, Paris, France
    Lancet Oncol 13:375-84. 2012
    ..In our phase 2 trial, we aimed to assess efficacy and safety of neoadjuvant bevacizumab combined with trastuzumab and chemotherapy in patients with primary HER2-positive inflammatory breast cancer...
  55. pmc A "class action" against the microenvironment: do cancer cells cooperate in metastasis?
    François Clément Bidard
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    Cancer Metastasis Rev 27:5-10. 2008
    ..As a result, after completion of the metastatic process, the series of microenvironmental changes from the primary tumor to the metastatic site may promote colonization of metastases by nonmetastatic cancer cells of the primary tumor...
  56. ncbi request reprint Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases
    Regis Peffault De Latour
    Department of Clinical Hematology, Institut Curie, France
    Am J Clin Oncol 27:333-6. 2004
    ..05, Mann-Whitney U test). Breast cancers are associated with ITP, with a parallel course of the two diseases in one third of cases. This may suggest tumor-induced immunologic thrombocytopenia...
  57. doi request reprint [Disseminated and circulating tumor cells in gastrointestinal oncology]
    Hélène Vegas
    Institut Curie, 26, rue d Ulm, 75005 Paris, France
    Bull Cancer 99:535-44. 2012
    ....
  58. doi request reprint Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, 75005 Paris Cedex, France
    Eur J Cancer 45:1979-86. 2009
    ....
  59. doi request reprint Management of phyllodes breast tumors
    Eugenie Guillot
    Department of Surgery, Institut Curie, Paris, France
    Breast J 17:129-37. 2011
    ..Genetic analysis will potentially supplement classical histologic examination in order to improve our management of these tumors. The role of adjuvant treatments is unproven and must be considered on a case-by-case basis...
  60. doi request reprint Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer
    F C Bidard
    Department of Medical Oncology, Institut Curie, Paris, France
    Ann Oncol 20:1836-41. 2009
    ..Our aim was to determine whether BM DTC detection could be related to specific locoregional dissemination of cancer cells, according to radiotherapy volumes...
  61. pmc Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery
    Marie Gosset
    Department of Surgery, Institut Curie, 75005, Paris, France
    PLoS ONE 11:e0159888. 2016
    ..A short time between primary cancer and IBTR is a prognostic factor but no clinically relevant threshold was determined. Classification of IBTR may help tailor treatment strategies...
  62. pmc Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population
    Lea Rossi
    Institut Curie, Paris, France Equipe d accueil 7285, Risk and Safety in Clinical Medicine for Women and Perinatal Health, University Versailles Saint Quentin, Montigny le Bretonneux, France
    PLoS ONE 10:e0132853. 2015
    ..The aim of this study was to evaluate the effect of adjuvant chemotherapy on the survival of breast cancer patients in an unselected population...
  63. doi request reprint Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types
    Ronald Lebofsky
    Circulating Cancer Biomarkers Lab, SIRIC, Translational Research Department, Institut Curie, Paris, France
    Mol Oncol 9:783-90. 2015
    ....
  64. doi request reprint FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool
    Karla Perez-Toralla
    Macromolecules and Microsystems in Biology and Medicine, Institut Curie, Centre National de Recherche Scientifique, Universite Pierre et Marie Curie, UMR 168, 75005 Paris, France
    Lab Chip 15:811-22. 2015
    ..The protocol can be fully automated, and its consumption of samples and DNA probes is reduced as compared to glass slide protocols by a factor of at least 10. The total duration of the assay is divided by two. ..
  65. doi request reprint Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
    François Clément Bidard
    Department of Medical Oncology and SIRIC, Institut Curie, Paris, France Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 15:406-14. 2014
    ..We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data...
  66. ncbi request reprint Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies
    Veronique Dieras
    Department of Medical Oncology, Institut Curie, Paris, France
    Clin Cancer Res 11:6256-60. 2005
    ..The purpose of this study was to investigate the safety and tolerability of MS209, a potent inhibitor of P-glycoprotein, when given in combination with docetaxel and to determine whether MS209 affects docetaxel pharmacokinetics...
  67. doi request reprint Microfluidic: an innovative tool for efficient cell sorting
    Julien Autebert
    Institut Curie, Centre National de la Recherche Scientifique, Universite Pierre et Marie Curie, Unité Mixte de Recherche 168, 75005 Paris, France
    Methods 57:297-307. 2012
    ..We document potential applications, discuss the main advantages and limitations of different approaches, and tentatively outline the main remaining challenges in this fast evolving field...
  68. doi request reprint [Brain metastasis of breast tumors and blood brain barrier]
    Veronique Dieras
    Institut Curie, Departement d Oncologie Medicale, Unité d investigation clinique, 25, rue d Ulm, 75248 Paris Cedex 05, France
    Bull Cancer 98:385-9. 2011
    ..Specific strategies are needed to fight brain metastatic disease. Preclinical models for brain metastasis have been developed, yielding mechanistic molecular knowledge and new therapeutic approaches...
  69. ncbi request reprint Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients?
    Veronique Girre
    Institut Curie, Departement d Oncologie Medicale, Paris, France
    J Gerontol A Biol Sci Med Sci 63:724-30. 2008
    ..This study was performed to describe the treatment plan modifications after a geriatric oncology clinic. Assessment of health and functional status and cancer assessment was performed in older cancer patients referred to a cancer center...
  70. ncbi request reprint Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction
    P de Cremoux
    Departement de Biologie des Tumeurs, Institut Curie, Paris, France
    Clin Cancer Res 6:3117-22. 2000
    ..The clinical significance of blood-borne cells in breast cancer, especially at the operable stage, may be investigated by following these patients...
  71. ncbi request reprint Interaction between Herceptin and taxanes
    V Dieras
    Department of Medical Oncology, Institut Curie, Service de Medecine Oncologique, Paris, France
    Oncology 61:43-9. 2001
    ..The results of the studies to date indicate that regimens combining Herceptin with 3-weekly and weekly taxane are effective and well tolerated...
  72. pmc Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)
    J Y Pierga
    Oncology Department, Institut Curie, Paris, France
    Br J Cancer 77:1474-9. 1998
    ..Haematological toxicity was more severe in the bolus-treated group (P = 0.05), as were nausea and vomiting (P < or = 0.01). We conclude that the two regimens appeared equally effective but have different toxicities...
  73. pmc Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy
    L Chauveinc
    Radiotherapy Department, Institut Curie, 26 Rue d Ulm, 75248 Paris, Cedex 05, France
    Br J Cancer 89:2057-61. 2003
    ..Perhaps reduction of doses of chemotherapy must be discussed for older patients...
  74. pmc Second malignancies after breast cancer: the impact of different treatment modalities
    Y M Kirova
    Department of Radiation Oncology, Institut Curie, Paris, France
    Br J Cancer 98:870-4. 2008
    ..This increase may be related to adjuvant treatment in some cases. However, the absolute risk is small...
  75. pmc High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies
    M A Bollet
    Department of Radiation Oncology, Institut Curie, Paris Cedex 05, Paris 75248, France
    Br J Cancer 98:734-41. 2008
    ..The lobular type had no adverse effect, neither on locoregional control nor on overall survival, even in the group of patients treated with breast conservation...
  76. pmc Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues
    A Vincent-Salomon
    Institut Curie, Paris, France
    J Clin Pathol 61:570-6. 2008
    ..Finally, this review addresses the main biological questions raised by disseminated tumour cells, in particular understanding tumour dormancy and identifying metastatic stem cells...
  77. ncbi request reprint Challenges in the stratification of breast tumors for tailored therapies
    J P Thiery
    Institut Curie, 26, rue d Ulm, 75248 Paris Cedex 05
    Bull Cancer 93:E81-9. 2006
    ....
  78. doi request reprint [Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy]
    Y M Kirova
    Département d Oncologie Radiothérapie, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Cancer Radiother 13:276-80. 2009
    ..Prospective monocentric study of the skin and heart tolerance of a concurrent administration of trastuzumab (T) and radiotherapy (RT) for breast cancer (BC)...
  79. pmc HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
    A Vincent-Salomon
    Department of Tumor Biology, Institut Curie, Paris, France
    Br J Cancer 96:654-9. 2007
    ..Therefore, the efficiency of anti-HER2 adjuvant therapy could be evaluated, in a clinical trial, by sequential detection of HER2-positive micrometastatic cells within the bone marrow, before and after treatment...
  80. doi request reprint Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients
    Jordan Madic
    Laboratory of Circulating Tumor Biomarkers, SIRIC, Institut Curie, Paris, France INSERM U830, Paris, France
    Int J Cancer 136:2158-65. 2015
    ..Here, absence of prognostic impact of baseline ctDNA level suggests that mechanisms of ctDNA release in metastatic TNBC may involve, beyond tumor burden, biological features that do not dramatically affect patient outcome...
  81. doi request reprint [Circulating tumor cells: liquid biopsy]
    Catherine Alix-Panabieres
    Laboratoire cellules circulantes rares humaines, département de biopathologie cellulaire et tissulaire des tumeurs, Institut de Recherche en Biothérapie, Hopital Saint Eloi, CHRU, 80, avenue Augustin Fliche, Montpellier, France, Universite Montpellier 1, EA2415 Épidémiologie, biostatistiques et santé publique, Institut Universitaire de Recherche Clinique, 641, avenue du Doyen Gaston Giraud, 34093 Montpellier, France
    Bull Cancer 101:17-23. 2014
    ..The analytical specificity and clinical utility of these methods must be demonstrated in large prospective multicenter studies to reach the high level of evidence required for their introduction into clinical practice. ..
  82. ncbi request reprint [At last, an effective therapy for non-differentiated GI sarcomas (gastro intestinal stromal tumor)]
    G Des Guetz
    Departement de Medecine, Institut Curie, Paris, France
    J Chir (Paris) 139:268-73. 2002
    ..This new drug could significantly improve the prognosis of these aggressive chemoresistant tumors...
  83. pmc Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
    Maura Campitelli
    Department of Radiation Oncology, Institut Curie, Hospital, Paris, France
    PLoS ONE 7:e43393. 2012
    ..To determine whether the sequence of the cell-viral junction could be used in clinical practice as a specific marker of ctDNA, we analyzed a series of cervical cancer patient serums...
  84. pmc Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays
    Antoine Emmanuel Saliba
    Institut Curie, Centre National de la Recherche Scientifique, Universite Pierre et Marie Curie, Unité Mixte de Recherche 168, 75005 Paris, France
    Proc Natl Acad Sci U S A 107:14524-9. 2010
    ..It requires at least 10 times smaller sample volume and cell numbers than cytometry, potentially increasing the range of indications and the success rate of microbiopsy-based diagnosis, and reducing analysis time and cost...
  85. doi request reprint [Management of malignant phyllodes tumors of the breast: the experience of the Institut Curie]
    S Haberer
    Département de Radiothérapie Oncologique, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Cancer Radiother 13:305-12. 2009
    ..Given the scarcity of malignant phyllode tumours of the breast and the absence of consensus regarding their management justify the need for institutional retrospective evaluations of clinical practices...
  86. doi request reprint [Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]
    Jean Yves Pierga
    Universite Paris Descartes, Institut Curie, Departement d Oncologie Medicale, 26, rue d Ulm, 75005 Paris, France
    Bull Cancer 101:780-8. 2014
    ..The safety analysis in the various sub-groups of grade 3-5 adverse events of particular interest to bevacizumab of this study was comparable to the safety data of randomized phase III studies...
  87. doi request reprint Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study
    Francoise Laroche
    Pain Clinic, Saint Antoine Hospital, Paris, France
    J Pain 15:293-303. 2014
    ....
  88. pmc Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, Paris, France
    Cancer Metastasis Rev 32:179-88. 2013
    ..These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients...
  89. doi request reprint Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma
    François Clément Bidard
    Department of Medical Oncology, Institut Curie, Paris, France Laboratory of Circulating Tumor Biomarkers, Institut Curie, Paris, France
    Int J Cancer 134:1207-13. 2014
    ..CTC detection can be performed in every patient but, in patients with detectable mutations, ctDNA was more frequently detected than CTC and has possibly more prognostic value...
  90. pmc Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 19:1596-602. 2013
    ..The objective here was to develop and validate nomograms that combined baseline CTC counts and the other prognostic factors to assess the outcome of individual patients starting first-line treatment for MBC...
  91. doi request reprint [An unusual adrenal tumor: Ewing tumor]
    Julie Gonin
    Service d Anatomie et Cytologie Pathologiques, Hopital Cochin, Paris, France
    Ann Pathol 31:28-31. 2011
    ..Diagnosis of Ewing tumor is based on pathologic and molecular findings, especially in atypical cases...
  92. ncbi request reprint Treatment of malignant gliomas in the elderly
    J Y Pierga
    Radiation Oncology Department, Salpetriere Hospital, Paris, France
    J Neurooncol 43:187-93. 1999
    ..Further studies are needed to define the most appropriate dose of radiotherapy and to evaluate further the risk/benefit ratio of a reduced dose chemotherapy in this population...
  93. ncbi request reprint Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program
    J Y Pierga
    Institut Curie, 75005 Paris, France
    Breast Cancer Res Treat 88:117-29. 2004
    ..A retrospective source review identifying predictive factors and assessing safety and efficacy in pretreated metastatic breast cancer (MBC) patients treated with capecitabine in a French compassionate-use program...
  94. doi request reprint [Circulating tumor cells and breast cancer: detection techniques and clinical results]
    F C Bidard
    Departement d Oncologie Medicale, Institut Curie, 26, rue d Ulm, 75248 Paris Cedex 05, France
    Bull Cancer 96:73-86. 2009
    ..We review here the different detection techniques and their clinical results in breast cancer patients...
  95. pmc Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer
    J Y Pierga
    Physiopathology Laboratory and Medical Oncology Department, Institute Curie, Paris, France
    Br J Cancer 76:537-40. 1997
    ..91, P = 0.05) to response. These data suggest that PAI-1 is not a predictive marker of response to chemotherapy in breast cancer and that its level is not altered by neoadjuvant chemotherapy...
  96. pmc Are ipsilateral breast tumour invasive recurrences in young (< or =40 years) women more aggressive than their primary tumours?
    B Sigal-Zafrani
    Department of Pathology, Institut Curie, Paris, France
    Br J Cancer 97:1046-52. 2007
    ..24 (0.92-5.41); P=0.08). IBTRs did not display features of higher aggressiveness than PTs. Neither clinical nor histological definition of a true recurrence could be established other than the conservation of the histological type...
  97. ncbi request reprint A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
    ..We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis...
  98. ncbi request reprint Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma
    Catherine Delbaldo
    Department of Medicine and Department of Clinical Biochemistry, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 41:1739-45. 2005
    ..From this study, we conclude that there is no evidence of pharmacokinetic interaction between irinotecan and cetuximab...